Jun 28, 2022 Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
May 24, 2022 Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
Apr 13, 2022 Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
Oct 5, 2021 Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Jun 29, 2021 Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
Apr 29, 2021 Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event
